Fortress Biotech Stock Forecast, Price & News

-0.10 (-2.78 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume832,855 shs
Average Volume1.40 million shs
Market Capitalization$340.62 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

Fortress Biotech logo

About Fortress Biotech

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.37 out of 5 stars

Medical Sector

783rd out of 2,100 stocks

Pharmaceutical Preparations Industry

390th out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

Is Fortress Biotech a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Fortress Biotech stock.
View analyst ratings for Fortress Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Fortress Biotech?

Wall Street analysts have given Fortress Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fortress Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Fortress Biotech

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) issued its quarterly earnings data on Monday, May, 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.05. The biopharmaceutical company had revenue of $11.59 million for the quarter, compared to analysts' expectations of $13.51 million. Fortress Biotech had a negative net margin of 97.09% and a negative trailing twelve-month return on equity of 23.41%.
View Fortress Biotech's earnings history

How has Fortress Biotech's stock been impacted by Coronavirus (COVID-19)?

Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FBIO stock has increased by 117.4% and is now trading at $3.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for FBIO?

6 analysts have issued 1-year target prices for Fortress Biotech's stock. Their forecasts range from $5.00 to $21.00. On average, they anticipate Fortress Biotech's share price to reach $10.60 in the next twelve months. This suggests a possible upside of 202.9% from the stock's current price.
View analysts' price targets for Fortress Biotech
or view top-rated stocks among Wall Street analysts.

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 66, Pay $576.65k)
  • Mr. Michael S. Weiss, Vice Chairman & Exec. Vice Chairman of Strategic Devel. (Age 55, Pay $576.63k)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 59, Pay $583.11k)
  • Dr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 67, Pay $386.5k)
  • Dr. Thomas F. Schaible, Project Leader of Inflammatory Bowel Disease

Who are some of Fortress Biotech's key competitors?

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (8.85%), BlackRock Inc. (4.99%), Opaleye Management Inc. (3.98%), Geode Capital Management LLC (1.20%), Northern Trust Corp (0.74%) and Shikiar Asset Management Inc. (0.61%). Company insiders that own Fortress Biotech stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends for Fortress Biotech

Which major investors are selling Fortress Biotech stock?

FBIO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Acadian Asset Management LLC, Nantahala Capital Management LLC, Morgan Stanley, HighTower Advisors LLC, Northern Trust Corp, Bank of New York Mellon Corp, and Los Angeles Capital Management LLC. Company insiders that have sold Fortress Biotech company stock in the last year include Eric K Rowinsky, and Robyn Hunter.
View insider buying and selling activity for Fortress Biotech
or view top insider-selling stocks.

Which major investors are buying Fortress Biotech stock?

FBIO stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, BlackRock Inc., Prudential Financial Inc., Perkins Capital Management Inc., Goldman Sachs Group Inc., Man Group plc, GSA Capital Partners LLP, and Barclays PLC. Company insiders that have bought Fortress Biotech stock in the last two years include Lindsay A Md Rosenwald, and Malcolm Hoenlein.
View insider buying and selling activity for Fortress Biotech
or or view top insider-buying stocks.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $3.50.

How much money does Fortress Biotech make?

Fortress Biotech has a market capitalization of $340.62 million and generates $45.60 million in revenue each year. The biopharmaceutical company earns $-46,530,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Fortress Biotech have?

Fortress Biotech employs 111 workers across the globe.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is

Where are Fortress Biotech's headquarters?

Fortress Biotech is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.